Department of Obstetrics and Gynecology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.
Virchows Arch. 2010 Apr;456(4):433-41. doi: 10.1007/s00428-010-0884-x. Epub 2010 Feb 13.
To study the steroid hormone-induced growth mechanisms of endometriosis, the immunohistochemical expression of steroid hormone receptor cofactors was investigated in 37 cases of endometriotic epithelia and was compared with that of eutopic endometria of identical patients. The expression of steroid receptor coactivators (p300/CBP and SRC-1) and corepressors (NCoR and SMRT) was examined in relation to the estrogen receptor (ER), the progesterone receptor (PR), and Ki-67. Results of immunostaining were indicated as a "positivity index" (PI, full score; 100). The expression of ER and PR in endometriotic epithelia largely resembled that in eutopic endometria, however, the expression of Ki-67 in the proliferative phase (PI 13.8 +/- 2.4, mean +/- SD) was significantly lower than that in eutopic endometria (32.6 +/- 10.6). The expression of SRC-1 in eutopic endometria was increased in the proliferative phase (56.5 +/- 16.8) and decreased in the secretory phase (14.8 +/- 6.9). In endometriosis, however, the PI for SRC-1 did not show apparent cyclic changes during the menstrual cycle. Moreover, the expression of SRC-1 in endometriotic epithelia in the proliferative phase was significantly lower than that in eutopic endometria. These findings suggested the reduced proliferative activity in endometriotic epithelia to be related to the reduced expression of SRC-1.
为了研究子宫内膜异位症的甾体激素诱导生长机制,研究人员调查了 37 例子宫内膜异位症上皮组织中甾体激素受体共激活因子的免疫组织化学表达,并与相同患者的在位子宫内膜进行了比较。研究人员还检查了甾体受体共激活因子(p300/CBP 和 SRC-1)和共抑制因子(NCoR 和 SMRT)的表达与雌激素受体(ER)、孕激素受体(PR)和 Ki-67 的关系。免疫染色结果用“阳性指数”(PI,满分 100)表示。子宫内膜异位症上皮组织中 ER 和 PR 的表达与在位子宫内膜非常相似,然而,增殖期 Ki-67 的表达(PI 为 13.8 +/- 2.4,平均值 +/- 标准差)明显低于在位子宫内膜(32.6 +/- 10.6)。在增殖期,SRC-1 在在位子宫内膜中的表达增加(56.5 +/- 16.8),在分泌期减少(14.8 +/- 6.9)。然而,在子宫内膜异位症中,SRC-1 的 PI 在月经周期中没有明显的周期性变化。此外,子宫内膜异位症上皮组织中 SRC-1 的表达在增殖期明显低于在位子宫内膜。这些发现表明,子宫内膜异位症上皮组织增殖活性降低可能与 SRC-1 表达降低有关。